Prague Med. Rep. 2021, 122, 140-180

Valproate-associated Movement Disorder: A Literature Review

Jamir Pitton Rissardo1, Ana Letícia Fornari Caprara1, Ícaro Durante2

1Department of Medicine, Federal University of Santa Maria, Santa Maria, Brazil
2Department of Medicine, Federal University of Fronteira Sul, Passo Fundo, Brazil

Received February 21, 2020
Accepted August 22, 2021


1. Abreu, L. N., Issler, C., Lafer, B. (2009) Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient. Aust. N. Z. J. Psychiatry 43(5), 484–485.
2. Aguglia, U., Gambardella, A., Zappia, M., Valentino, P., Quattrone, A. (1995) Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin. Electroencephalogr. Clin. Neurophysiol. 94(2), 103–108. <>
3. Aguilar, L. G., Ondo, W. G. (2008) Exploring the relationship between drug-induced parkinsonism and tardive dyskinesias. Mov. Disord. 23.
4. Alonso-Navarro, H., Adeva-Bartolomé, T., Jiménez-Jiménez, F. (2007) Tic disorders associated to epilepsy: 2 cases. Mov. Disord. 22, 283.
5. Alvarez-Gomez, M. J., Vaamonde, J., Narbona, J., Barao, M., Barona, P., Brannan, T., Gudin, M., Ibañez, R. (1993) Parkinsonian syndrome in childhood after sodium valproate administration. Clin. Neuropharmacol. 16(5), 451–455. <>
6. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Association Publishing, Washington D.C.
7. Andrade, R., García-Espinosa, A., Pérez-Montoto, A., Toledo-Sotomayor, G., Remón-González, Y., Frades-García, V. (2010) Síntomas neuropsiquiátricos causados por ácido valproico. Rev. Neurol. 50(1), 62–63.
8. Armon, C., Shin, C., Miller, P., Carwile, S., Brown, E., Edinger, J. D., Paul, R. G. (1996) Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 47(3), 626–635. <>
9. Athauda, D., Batley, R., Ellis, C. (2015) Clinically silent idiopathic Parkinson’s disease unmasked by valproate use: a brief report. Aging Clin. Exp. Res. 27(3), 387–390. <>
10. Aukst-Margetić, B., Margetić, B. (2008) Stuttering as a side-effect of divalproex sodium. Psychiatry Clin. Neurosci. 62(6), 748–748.
11. Aykut, D. S., Aral, G., Tiryaki, A. (2018) Parkinsonism due to the use of long-term high-dose valproic acid in an elderly patient with mania syndrome: a case report and literature review. Psychiatry and Behavioral Sciences 8(4), 199–203.
12. Baf, M. M., Subhash, M., Lakshmana, K. M., Rao, B. S. R. (1994) Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem. Int. 24(1), 67–72.
13. Baizabal-Carvallo, J. F., Alonso-Juarez, M. (2021) Valproate-induced rest tremor and parkinsonism. Acta Neurol. Belg. 121, 515–519. <>
14. Barroso, B. (2002) Reversible parkinsonism induced by prolonged treatment with valproate. Therapie 57(4), 410–411. (in French)
15. Bayram, E., Karakaya, P., Topcu, Y., Yis, U., Hiz, S. (2013) Acute cervical dystonia after the first dose of butamirate citrate. Pediatr. Emerg. Care 29(1), 80–81. <>
16. Bennett, A., Rosen, J. (2019) Valproate-induced parkinsonism: A literature review and case series. American Psychiatric Association Annual Meeting.
17. Bermudez, M., Gracia, D., Garcia, D., Cunha, E., Campos, F., Santistevan, T., Motta, G. (2017) Trismus secondary to valproate treatment in a woman with bipolar disorder: a case report. Archives of Clinical Psychiatry (Sao Paulo) 44(5), 137–137. <>
18. Bhattacharjee, S., Shankar, P. V., Elkider, M. (2016) Dopamine transporter single-photon emission computed tomography brain scan: A reliable way to distinguish between degenerative and drug-induced parkinsonism. Indian J. Nucl. Med. 31(3), 249–250. <>
19. Bhattacharjee, S., Chalissery, A. J., Barry, T., O’Sullivan, D., O’Connell, M., Lynch, T. (2017) Referral practice, reporting standards, and the impact of dopamine transporter scans done in a tertiary hospital. Neurol. India 65(6), 1264–1270. <>
20. Bodensteiner, J., Morris, H., Golden, G. (1981) Asterixis associated with sodium valproate. Neurology 31(2), 194–195. <>
21. Bondon-Guitton, E., Perez-Lloret, S., Bagheri, H., Brefel, C., Rascol, O., Montastruc, J.-L. (2011) Drug-induced parkinsonism: A review of 17 years’ experience in a regional pharmacovigilance center in France. Mov. Disord. 26(12), 2226–2231. <>
22. Borroni, B., Rosati, A., Costanzi, C., Zulli, R., Mardighian, D., Gasparotti, R., Padovani, A. (2007) Multiple system atrophy due to prolonged valproic acid treatment. Int. Psychogeriatr. 19(4), 780–782. <>
23. Botturi, A., Silvani, A., Pravettoni, G., Paoli, R. A., Lucchiari, C. (2016) Reversible valproate induced Pisa syndrome and parkinsonism in a neuro-oncology patient with depression and epilepsy. Case Rep. Neurol. 8(2), 115–119. <>
24. Bowden, C. L. (2003) Valproate. Bipolar Disord. 5(3), 189–202. <>
25. Bowdle, T., Patel, I., Wilensky, A., Comfort, C. (1979) Hepatic failure from valproic acid. N. Engl. J. Med. 301(8), 435–436.
26. Brefel-Courbon, C., Gardette, V., Ory, F., Montastruc, J. L. (2006) Drug-induced myoclonus: A French pharmacovigilance database study. Neurophysiol. Clin. 36(5–6), 333–336. <>
27. Brugger, F., Bhatia, K. P., Besag, F. M. C. (2016) Valproate-associated parkinsonism: A critical review of the literature. CNS Drugs 30(6), 527–540. <>
28. Bruno, E., Holmes, P., Koutroumanidis, M. (2016) A complex hyperkinesia induced by valproate. Mov. Disord. Clin. Pract. 3(5), 513–514. <>
29. Campostrini, R., Paganini, M., Boncinelli, L., Zaccara, G., Arnetoli, G., Zappoli, R. (1983) Alterations of the state of consciousness induced by valproic acid: 6 case reports. Riv. Patol. Nerv. Ment. 104(1), 23–34. (in Italian)
30. Caruana Galizia, E., Isaacs, J. D., Cock, H. R. (2017) Non-hyperammonaemic valproate encephalopathy after 20 years of treatment. Epilepsy Behav. Case Rep. 8, 9–11. <>
31. ClinCalc (2020) The Top 300 of 2020. Available at:
32. Clos, F. H. (2001) Acute akathisia and sodium valproate. Int. J. Psychiatry Clin. Pract. 5(3), 219–222. <>
33. Cloyd, J. C., Kriel, R. L., Jones-Saete, C. M., Ong, B. Y., Jancik, J. T., Remmel, R. P. (1992) Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J. Pediatr. 120(4 Pt 1), 634–638. <>
34. Conforti, D., Borgherini, G., Fiorellini Bernardis, L. A., Magni, G. (1999) Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination. Int. Clin. Psychopharmacol. 14(3), 197–198. <>
35. Czarnecki, K., Kumar, N., Josephs, K. A. (2008) Parkinsonism and tardive antecollis in frontotemporal dementia – Increased sensitivity to newer antipsychotics? Eur. J. Neurol. 15(2), 199–201. <>
36. Dal, S., Whyte, S. (2019) 035 Valproate-induced parkinsonism “an early warning”: case reports and review of literature. J. Neurol. Neurosurg. Psychiatry 90(e7), A12–A12.
37. Davoudi-Monfared, E., Radmehr, M., Ghaeli, P., Mousavi, M. (2019) A case series of severe hyperammonemia encephalopathy related to valproate: Can antipsychotics increase the risk? Iran. J. Psychiatry 14(3), 248–252.
38. De Dios, C., Fudio, S., Lorenzo, A. (2011) Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine. J. Clin. Pharm. Ther. 36(3), 430–432. <>
39. De Vries, E., Schoonvelde, M., Schumacher, G. (2018) No longer lost in translation: Evidence that Google Translate works for comparative bag-of-words text applications. Polit. Anal. 26(4), 417–430. <>
40. Dealberto, M.-J. C. C., Sarazin, F. F. A. (2008) Valproate-induced hyperammonemic encephalopathy without cognitive sequelae: A case report in the psychiatric setting. J. Neuropsychiatry Clin. Neurosci. 20(3), 369–371. <>
41. del Real Francia, M. A., Sanz Martínez, J., Vaamonde Gamo, J., Gudín Rodríguez-Magariños, M., Ibáñez Alonso, R., Riñón, V. (1995) Parkinsonism induced by sodium valproate. Neurologia 10(9), 381–383. (in Spanish)
42. Dergalust, S., Ferrer, M., Cheng, E., Sayers, J. (2005) Drug-induced movement disorders caused by medications other than dopamine receptor blockers in the Veteran population. Mov. Disord. 20, 17–18.
43. Desai, D., Desai, S. (2015) Spectrum of disorders presenting as secondary Parkinsonism in a rural based medical teaching college in Western India. Mov. Disord. 30.
44. Dick, D., Saunders, M. (1980) Extrapyramidal syndrome with sodium valproate. Br. Med. J. 280(6208), 189. <>
45. Duggal, H. S. (2008) Acute Pisa syndrome and pharnygolaryngeal dystonia due to ziprasidone. J. Neuropsychiatry Clin. Neurosci. 20(1), 108–109. <>
46. Dunayevich, E., Strakowski, S. M. (1999) Olanzapine-induced tardive dystonia. Am. J. Psychiatry 156(10), 1662. <>
47. Easterford, K., Clough, P., Kellett, M., Fallon, K., Duncan, S. (2004) Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 62(8), 1435–1437. <>
48. Evans, M. D., Shinar, R., Yaari, R. (2011) Reversible dementia and gait disturbance after prolonged use of valproic acid. Seizure 20(6), 509–511. <>
49. Fan, C. C., Huang, M. C., Liu, H. C. (2008) Lamotrigine might potentiate valproic acid-induced hyperammonemic encephalopathy. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(7), 1747–1748. <>
50. Faridhosseini, F., Omidi-Kashani, F., Baradaran, A. (2015) Pisa syndrome associated with clozapine: A rare case report and literature review. Spine Deform. 3(4), 386–389. <>
51. Ferrari, A., De Merra, F., Filosto, M., Leonardi, A. (2004) Sodium valproate induced parkinsonism. Epilepsia 45, 132.
52. Foley, C., Slevin, J., Kasarskis, E. (2002) Divalproex-induced parkinsonism: A retrospective review of cases. Mov. Disord. 17, 250–251.
53. Friis, T., Christensen, T. R., Gerlach, J. (1983) Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr. Scand. 67(3), 178–187. <>
54. Froomes, P. R., Stewart, M. R. (1994) A reversible parkinsonian syndrome and hepatotoxicity following addition of carbamazepine to sodium valproate. Aust. N. Z. J. Med. 24(4), 413–414. <>
55. Gara, L., Roberts, W. (2000) Adverse response to methylphenidate in combination with valproic acid. J. Child Adolesc. Psychopharmacol. 10(1), 39–43. <>
56. Gardner, T. M., Aziz, R., Muralee, S., Tampi, R. R. (2009) Valproic acid-induced myoclonus in a demented patient: a case report. Case Rep. Med. 2009, 392091. <>
57. Gastaut, J. L., Mege, J. L. (1985) Encephalopathy with asterixis induced by sodium valproate. Role of hyperammonemia without hepatic insufficiency. Presse Med. 14(7), 431. (in French)
58. Gaubert, M. L., Cougnaud, A., Ghali, A., Bruhat, C., Diquet, B., Berrut, G. (2006) Loss of autonomy related to valproic acid intake. J. Am. Geriatr. Soc. 54(12), 1971–1971. <>
59. Giordano, A., Amboni, M., Tessitore, A. (2014) Valproate-induced generalized choreoathetosis. Mov. Disord. Clin. Pract. 1(3), 271–272. <>
60. Gosala Raja Kukkuta, S., Srinivas, M., Raghunandan, N., Thomas, M., Prabhu, A., Laly, M. (2013) Reversible vertical gaze palsy in sodium valproate toxicity. J. Neuroophthalmol. 33(2), 202–203. <>
61. Gunal, D. I., Guleryuz, M., Bingol, C. A. (2002) Reversible valproate-induced choreiform movements. Seizure 11(3), 205–206. <>
62. Gwinn, K. A., Caviness, J. N. (1997) Risperidone‐induced tardive dyskinesia and parkinsonism. Mov. Disord. 12(1), 119–121. <>
63. Habermeyer, B., Rabovsky, K., Jentzsch, C., Pinhard, K., Müller-Spahn, F. (2007) Cervical dystonia due to interaction of valproic acid and quetiapine. J. Clin. Psychopharmacol. 27(4), 396–397. <>
64. Hall, D. A., Ringel, S. P. (2004) Adult nonketotic hyperglycinemia (NKH) crisis presenting as severe chorea and encephalopathy. Mov. Disord. 19(4), 485–486. <>
65. Hassamal, S., Waller, S., Reese, K., Testa, C. (2016) Reversible valproic acid-induced parkinsonism and cognitive impairment in an elderly patient with bipolar disorder I. Turk Psikiyatri Derg. 27(3), 213–217. (in Turkish, English)
66. He, Z. F., Chen, J., Zhou, C. N., Rao, Z., Wang, X. H. (2017) Disabling tremor induced by long-term use of sodium valproate and lamotrigine: case report. Medicine 96(47), e8711. <>
67. Henry, T. R. (2003) The history of valproate in clinical neuroscience. Psychopharmacol. Bull. 37, 5–16 (Suppl. 2).
68. Hommet, C., Mondon, K., de Toffol, B., Constans, T. (2007) Reversible cognitive and neurological symptoms during valproic acid therapy. J. Am. Geriatr. Soc. 55(4), 628–628. <>
69. Iijima, M. (2002) Valproate-induced parkinsonism in a demented elderly patient. J. Clin. Psychiatry 63(1), 75. <>
70. Irons, R., Joanna, B., Apurba, C. (2015) The role of DaT scan in drug induced Parkinsonism. Mov. Disord. 30.
71. Iuppa, C. A., Diefenderfer, L. A. (2013) Risperidone-induced Pisa syndrome in MS: Resolution with lurasidone and recurrence with chlorpromazine. Ann. Pharmacother. 47(9), 1223–1228. <>
72. Jamora, D., Lim, S.-H., Pan, A., Tan, L., Tan, E.-K. (2007) Valproate-induced Parkinsonism in epilepsy patients. Mov. Disord. 22(1), 130–133. <>
73. Jankovic, J., Tolosa, E. (2007) Parkinson’s Disease and Movement Disorders. Lippincott Williams and Wilkins, Baltimore.
74. Jopowicz, A., Kurkowska-Jastrzebska, I. (2014) Parkinsonian syndrome, a sporadic side effect of valproic acid. Pharmacother. Psychiatr. Neurol. 23(3–4), 199–205.
75. Kao, C.-D., Chen, W.-T., Chen, J., Yen, D.-J., Yiu, C.-H., Liao, K.-K. (2001) Valproate asterixis: a case report. Acta Neurol. Taiwan. 10(2), 123–126.
76. Khwaja, G. A., Ranjan, R., Gupta, M., Chowdhry, D., Hirve, M. (2010) Valproate-induced reversible “Parkinsonism Plus” syndrome. J. Indian Acad. Clin. Med. 11, 235–238.
77. Kim, H., Park, H., Sung, Y., Lee, H., Kim, D., Choi, S. (2018) Valproic acid related reversible parkinsonism. Asian Oceanian Congress of Neurology.
78. Kim, S. K., Oh, S. H., Kim, W. J. (2000) A case of valproate-induced reversible parkinsonism. J. Korean Neurol. Assoc. 18(5), 654.
79. Kiuru, S., Iivanainen, M. (1987) Camptocormia, a new side effect of sodium valproate. Epilepsy Res. 1(4), 254–257. <>
80. Kohlhase, K., Knake, S., Timmermann, L., Rosenow, F., Strzelczyk, A. (2019) Akinetisch-rigide Bewegungsstörungen unter Antikonvulsiva. DGNeurologie 2(4), 287–291. <>
81. Lance, J., Anthony, M. (1977) Sodium valproate and clonazepam in the treatment of intractable epilepsy. Arch. Neurol. 34(1), 14–17. <>
82. Lancman, M. E., Asconapé, J. J., Penry, J. K. (1994) Choreiform movements associated with the use of valproate. Arch. Neurol. 51(7), 702–704. <>
83. Lapierre, O., Dubreucq, J. L., Beauchemin, M. A., Vinet, B. (1999) Valproic acid intoxication in a patient with bipolar disorder and chronic uremia. Can. J. Psychiatry 44(2), 188.
84. Lautin, A., Stanley, M., Angrist, B., Gershon, S. (1979) Extrapyramidal syndrome with sodium valproate. Br. Med. J. 2(6197), 1035–1036. <>
85. Leclair-Visonneau, L., Rouaud, T., Debilly, B., Durif, F., Houeto, J.-L., Kreisler, A., Defebvre, L., Lamy, E., Volteau, C., Nguyen, J. M., Dily, S. L., Damier, P., Boutoleau-Bretonnière, C., Lejeune, P., Derkinderen, P. (2016) Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin. Neurol. Neurosurg. 146, 35–39. <>
86. Lee, K. U. (2004) A case of reversible parkinsonism induced by valproate in a patient with bipolar disorder. Korean J. Psychopharmacol. 15(1), 107.
87. Lee, S., Koh, S., Park, K., Lee, D. (2007) Early dystonia in probable Creutzfeldt-Jakob disease with diffusion weighted MR images. Mov. Disord. 22, 117–118.
88. Lempérière, T. (2001) Brief history of the development of valproate in bipolar disorders. Encephale 27(4), 365–372. (in French)
89. Lepping, P., Delieu, J., Mellor, R., Williams, J. H. H., Hudson, P. R., Hunter-Lavin, C. (2011) Antipsychotic medication and oxidative cell stress: a systematic review. J. Clin. Psychiatry 72(3), 273–285. <>
90. Lindbom, U., Taubert, B., Fahlqvist, M. S., Bergens, A., Kimland, E., Jonsson, E. W., Bergman, U. (2009) Reversible dementia-like condition and parkinsonism in an elderly woman. Idiosyncratic adverse effects connected to 11 years of antiepileptic medication. Lakartidningen 106(12), 863–865. (in Swedish)
91. Löscher, W. (2002) Basic pharmacology of valproate. CNS Drugs 16(10), 669–694. <>
92. Louter, M., Tromp, S. C. (2009) Parkinsonism due to the medication. Ned. Tijdschr. Geneeskd. 153, A336–A336. (in Dutch)
93. Lyell, V., Henderson, E., Ahearn, D., MacMahon, D. (2010) Multi-centre survey of new patients referred from primary care with parkinsonism what proportion are on medications which can cause drug induced parkinsonism? Mov. Disord. 25(7), 224.
94. Macphee, G. (2005) Valproate induced parkinsonism. J. R. Coll. Physicians Edinb. 35(3), 214.
95. Macphee, G. J. A., Stewart, D. A. (2007) Diagnosis of Parkinsonism in older patients receiving sodium valproate. Mov. Disord. 22(8), 1211–1211. <>
96. Mahmoud, F., Tampi, R. R. (2011) Valproic acid-induced parkinsonism in the elderly: A comprehensive review of the literature. Am. J. Geriatr. Pharmacother. 9(6), 405–412. <>
97. Makhlouf, S., Mansour, M., Msselmeni, M., Bedoui, I., Zaouali, J. (2018) Side effects of sodium valproate in a Tunisian population. Res. J. Nerv. Syst. 1(1), 8.
98. Mangewala, V., Sarwar, S., Rosenberger, R., Rais, T., Knox, M. (2013) Valproate-induced hyperammonemic encephalopathy: a case report. Innov. Clin. Neurosci. 10(5–6), 12–13.
99. Masmoudi, K., Gras-Champel, V., Bonnet, I., Pannier, M., Masson, H., Rosa, A., Andrejak, M. (2000) Dementia and extrapyramidal problems caused by long-term valproic acid. Therapie 55(5), 629–634.
100. Masmoudi, K., Gras-Champel, V., Masson, H., Andréjak, M. (2006) Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 39(1), 9–12. <>
101. Maximov, K., Maximov, G. (2008) Valproate-induced parkinsonism in epilepsy patient – A case report. Acta Medica Bulgarica XXXV(1/2008), 38–42.
102. Morrison, P. F., Sankar, R., Shields, W. D. (2006) Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. Pediatr. Neurol. 35(5), 356–358. <>
103. Mukherjee, S., Sen, S., Chatterjee, S. S., Biswas, A., Tripathi, S. K. (2015) Divalproex-induced stuttering: A rare case report. Eur. J. Psychol. Educ. Studies 2(1), 25.
104. Munhoz, R. P., Werneck, L. C., Teive, H. A. G. (2010) The differential diagnoses of parkinsonism: Findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin. Neurol. Neurosurg. 112(5), 431–435. <>
105. Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., Greenblatt, D. J. (1981) A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30(2), 239–245. <>
106. Nayak, R., Pandurangi, A., Bhogale, G., Patil, N., Chate, S. (2012) Asterixis (flapping tremors) as an outcome of complex psychotropic drug interaction. J. Neuropsychiatry Clin. Neurosci. 24(1), E26–E27. <>
107. Nouzeilles, M., García, M., Rabinowicz, A., Merello, M. (1999) Prospective evaluation of parkinsonism and tremor in patients treated with valproate. Parkinsonism Relat. Disord. 5(1–2), 67–68. <>
108. Nutt, J., Williams, A., Plotkin, C., Eng, N., Ziegler, M., Calne, D. (1979) Treatment of Parkinson’s disease with sodium valproate: Clinical, pharmacological, and biochemical observations. Can. J. Neurol. Sci. 6(3), 337–343. <>
109. Oh, J., Park, K. D., Cho, H. J., Choi, K. G., Jung, S. M. (2004) Spasmodic dysphonia induced by valproic acid. Epilepsia 45(7), 880–881. <>
110. Onofrj, M., Thomas, A., Paci, C. (1998) Reversible parkinsonism induced by prolonged treatment with valproate. J. Neurol. 245(12), 794–796. <>
111. Pal, G., Lin, M. M., Laureno, R. (2014) Asterixis: A study of 103 patients. Metab. Brain Dis. 29(3), 813–824. <>
112. Park-Matsumoto, Y. C., Tazawa, T. (1998) Valproate induced parkinsonism. No To Shinkei 50(1), 81–84.
113. Patel, S. R., Patel, K. P., Gupta, S. D., Malhotra, S. D., Patel, P. R. (2018) Valproate induced Parkinsonism. Natl. J. Integr. Res. Med. 9(6), 72–74.
114. Penot, J.-P., Pradeau, F. (2010) Syndrome démentiel et extrapyramidal iatrogène: Effet secondaire rare de l’association acide valproïque-aspirine. Presse Med. 39(2), 279–280. <>
115. Power, C., Blume, W., Young, G. (1990) Reversible parkinsonism associated with valproate therapy. Neurology 40, 139 (Suppl. 1).
116. Prakash, S., Harbo, T., Christensen, J. (2015) Valproate can induce reversible encephalopathy. Ugeskr. Laeger 177(20), 945–946 (in Danish).
117. Raja, M., Azzoni, A. (2002) Valproate and quetiapine overdose with benign outcome: a case report. Int. J. Psychiatry Clin. Pract. 6(3), 173–174. <>
118. Randhawa, J., Mehanna, R. (2019) Drug-induced parkinsonism may persist beyond two years after discontinuation of dopamine transmission blocking agents. Mov. Disord. 34, 599.
119. Reif, A., Hamelbeck, B., Pfuhlmann, B. (2003) Acute akinetic crisis with marked cognitive impairment due to valproate treatment. Int. J. Geriatr. Psychiatry 18(4), 356–357. <>
120. Reif, A., Leonhard, C., Mössner, R., Lesch, K.-P., Fallgatter, A. J. (2004) Encephalopathy and myoclonus triggered by valproic acid. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(6), 1061–1063. <>
121. Ricard, C., Martin, K., Tournier, M., Bégaud, B., Verdoux, H. (2005) A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder. Encephale 31(1), 98–101. (in French) <>
122. Rissardo, J. P., Caprara, A. L. F. (2019) Comment: Dystonia and asterixis in acute thalamic infarct: Proposed mechanism. Ann. Mov. Disord. 2(3), 138–139. <>
123. Rissardo, J. P., Caprara, A. L. F., Silveira, J. O. F. (2019) Valproic acid-associated pancytopenia: A dose-dependent adverse effect. Rom. J. Neurol. 18(3), 150–153. <>
124. Ristić, A. J., Vojvodić, N., Janković, S., Sindelić, A., Sokić, D. (2006) The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: A study of 364 patients with different types of epilepsy. Epilepsia 47(12), 2183–2185. <>
125. Rottach, K. G., Weiss-Brummer, J., Wieland, U., Schmauß, M. (2000) Valproinsäure als Phasenprophylaktikum Ein Fall von Valproat-Enzephalopathie. Nervenarzt 71(5), 401–403. <>
126. Salazar, Z., Tschopp, L., Calandra, C., Micheli, F. (2008) Pisa syndrome and parkinsonism secondary to valproic acid in Huntington’s disease. Mov. Disord. 23(16), 2430–2431. <>
127. Sarna, J., Pringsheim, T. (2011) Progressive supranuclear palsy-like phenotype associated with concomitant exposure to mood stabilizer and neuroleptic. Mov. Disord. 26.
128. Sasso, E., Delsoldato, S., Negrotti, A., Mancia, D. (1994) Reversible valproate-induced extrapyramidal disorders. Epilepsia 35(2), 391–393. <>
129. Sawle, G., Colebatch, J., Shah, A., Brooks, D., Marsden, C., Frackowiak, R. (1990) Striatal function in normal aging: Implications for Parkinson’s disease. Ann. Neurol. 28(6), 799–804. <>
130. Schreur, L., Middeljans-Tijssen, C. W., Hengstman, G. J. D., Olde Rikkert, M. G. M. (2009) Cognitieve stoornissen en parkinsonisme bij gebruik van valproïnezuur. Tijdschr. Gerontol. Geriatr. 40(1), 29–33. <>
131. Sechi, G. P., Conti, M., Sau, G. F., Cocco, G. A. (2008) Valproate-induced parkinsonism, glial cells and Alexander’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(5), 1351–1352. <>
132. Shill, H. A., Fife, T. D. (2000) Valproic acid toxicity mimicking multiple system atrophy. Neurology 55(12), 1936–1937. <>
133. Shirasaka, Y., Mitsuyoshi, I. (1999) A case of epileptic negative myoclonus: Therapeutic considerations. Brain Dev. 21(3), 209–212. <>
134. Silver, M., Factor, S. A. (2013) Valproic acid-induced parkinsonism: Levodopa responsiveness with dyskinesia. Parkinsonism Relat. Disord. 19(8), 758–760. <>
135. Simões, R., Inácio, N., Silva, V., Arraiolos, A., Alegria, P., Canas, N., Vale, J. (2016) Valproate-induced reversible parkinsonism – A case series. Mov. Disord. 31.
136. Sleegers, M. J. M., Beutler, J. J., Hardon, W. J., Berden, J. H. M., Verhave, J. C., Conemans, J. M. H., Hollander, D. A., Dautzenberg, P. L., Hoogeveen, E. K. (2010) Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus. J. Am. Geriatr. Soc. 58(4), 799–801. <>
137. Srinivasan, S., Lok, A. W. (2010) Valproate-induced reversible hemichorea. Mov. Disord. 25, 1511–1512. <>
138. Surendran, I., Sahoo, S., Gupta, G., Chauhan, N., Grover, S. (2016) Valproate-induced hyperammonemic encephalopathy in an elderly patient with bipolar disorder. J. Geriatr. Ment. Health 3(2), 172–175.
139. Tada, H., Ogihara, T., Nakamura, T., Sasayama, D., Sugiyama, N., Takahashi, Y., Washizuka, S., Amano, N. (2017) A case of severe parkinsonism in an elderly person induced by valproic acid. Psychogeriatrics 17(1), 76–77. <>
140. Teive, H. A. G., Souza, M., Antoniuk, S., Barbosa, E., Scaff, M., Werneck, L. (2004a) Status dystonicus: Report of four cases. Mov. Disord. 19, 114. <>
141. Teive, H. A. G., Troiano, A. R., Germiniani, F. M. B., Werneck, L. C. (2004b) Flunarizine and cinnarizine-induced parkinsonism: A historical and clinical analysis. Parkinsonism Relat. Disord. 10(4), 243–245. <>
142. Thome-Souza, S., Moreira, B., Valente, K. D. (2012) Late adverse effects of the coadministration of valproate and lamotrigine. Pediatr. Neurol. 47(1), 47–50. <>
143. Thygesen, K. S., Wolf, P. (2005) Valproate-caused encephalopathy. Ugeskr. Laeger 167(40), 3793–3794. (in Danish)
144. Toribio-Díaz, M. E., Morera-Guitart, J., Palao-Duarte, S. (2008) Reversible parkinsonism and cognitive impairment following treatment with valproate. Rev. Neurol. 47(7), 390–391. (in Spanish)
145. van de Velde, K., Cras, P., Helsen, G. (2011) Acute chorea caused by valproate in an elderly. Acta Neurol. Belg. 111(3), 220–221.
146. van der Zwan, A. Jr. (1989) Transient Parkinson syndrome and tremor caused by the use of sodium valproate. Ned. Tijdschr. Geneeskd. 133(24), 1230–1232. (in Dutch)
147. Vogt, H., Mothersill, I. (2000) Asterixis: An adverse event also with new anti-epileptic drugs. Epilepsia 41, 226 (Suppl. 7).
148. Wang, Y., Xia, J., Helfer, B., Li, C., Leucht, S. (2016) Valproate for schizophrenia. Cochrane Database Syst. Rev. 11(11), CD004028.
149. Werner, I., Bruchert, S., Meyer, K., Bohhalter, S. (2006) Dropped head syndrome in long-term care patients with chronic epilepsy and mental retardation-relationship to antiepileptic treatment. Mov. Disord. 21, 373.
150. Wils, V., Golüke-Willemse, G. (1997) Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient. Int. J. Geriatr. Psychiatry 12(2), 272. <<272::AID-GPS561>3.0.CO;2-V>
151. Yilmaz, A. E., Donmez, A., Orun, E., Tas, T., Isik, B., Sonmez, F. M. (2013) Methylphenidate-induced acute orofacial and extremity dyskinesia. J. Child Neurol. 28(6), 781–783. <>
152. Yohanan, M., Aulakh, J. S., Weith, J., Hawkins, J. W. (2006) Pisa syndrome in a patient in a wheelchair taking valproic acid. Am. J. Psychiatry 163(2), 325–326. <>
153. Yomtoob, J., Koloms, K., Bega, D. (2018) DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice. Parkinsonism Relat. Disord. 53, 37–41. <>
154. Yoon, J. H., Lee, P. H., Yong, S. W., Park, H. Y., Lim, T. S., Choi, J. Y. (2008) Movement disorders at a university hospital emergency room. An analysis of clinical pattern and etiology. J. Neurol. 255(5), 745–749. <>
155. Zaccara, G., Paganini, M., Campostrini, R., Arnetoli, G., Zappoli, R., Moroni, F. (1984) Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. Eur. Neurol. 23(2), 104–112. <>
156. Zadikoff, C., Munhoz, R. P., Asante, A. N., Politzer, N., Wennberg, R., Carlen, P., Lang, A. (2007) Movement disorders in patients taking anticonvulsants. J. Neurol. Neurosurg. Psychiatry 78(2), 147–151. <>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)